ExpreS2ion Biotech has reworked the phase I programme for ES2B-C001, its HER2-VLP active immunotherapy, adding a deeper translational analysis package and a maintenance phase – while reporting anti-HER2 antibody responses in all 9 evaluable patients. Key dates hold: an end-2026 primary readout and a mid-2027 phase II start. BioStock reached out to CEO Bent U. Frandsen about the redesign and what it signals.
Read the full interview at biostock.se:
Partner feedback reshapes ExpreS2ion's ES2B-C001 programme as responses hit 9 of 9
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/